InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,949.17
(
-0.60%
)
US TECH 100
20,347.60
(
0.00%
)
Dow Jones
43,750.86
(
-0.47%
)
Brent Oil
71.51
(
-0.97%
)
Bitcoin
88,003.99
(
0.75%
)
Post# of 253608
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120725
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 179395

Friday, 01/23/2015 6:02:22 PM

Friday, January 23, 2015 6:02:22 PM

Post# of 253608
FDA approves GSK/NVS’ Bexsero meningitis-B vaccine:

http://finance.yahoo.com/news/novartis-bexsero-vaccine-approved-fda-224202663.html

A similar vaccine from PFE, called Trumenba, was approved by the FDA in Oct 2014 (#msg-107658855). Both products are approved for people aged 10-25. Curiously, the two BLAs were submitted on the same day (#msg-103391258).

NVS developed Bexsero, but it now belongs to GSK as part of the asset transfer between these companies announced in Apr 2014 (#msg-100909502).

Please see #msg-79734337 for background info on meningitis B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up